newsfilter
← Latest News
Business Wire·

Compass Pathways Announces First Quarter 2026 Financial Results and Business Highlights

FDA granted Compass NDA rolling submission and review request, based on strength of Phase 3 data CNPV awarded for COMP360 in TRD, further accelerating momentum 26-week (Part B) data from COMP006, expected in